Slides
Page 1
October 24, 2026 ESMO 2026 UPDATE
Page 2
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 2 Safe Harbor Statement This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd. or Horizon Therapeutics plc (including the prospective performance and outlook ofHorizon’s business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this presentation and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturingour products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmentaleffort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercializationof our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipatedcosts, delays or failures to realize the benefits of the transactions. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. This presentation includes GAAP and non-GAAP financial measures. In accordance with the requirements of SEC Regulation G, reconciliations between these two measures, if these slides are in hard copy, accompany the hard copy presentation or, if these slides are delivered electronically, are available on the Company's website at www.amgen.com within the Investors section.
Page 3
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 3 Agenda Provided Oct. 24, 2026, as part of an oral presentation and is qualified Introduction Murdo Gordon, EVP, Global Markets & Policy Oncology Strategy and BiTE® Portfolio Jean-Charles Soria, SVP, Global Development, Oncology IMDELLTRA® Data Highlights from ESMO 2026 Dr. Charles Rudin, Director, Memorial Sloan Kettering Cancer Center Closing Remarks Jean-Charles Soria, SVP, Global Development, Oncology Q&A Murdo Gordon, EVP, Global Markets & Policy Jean-Charles Soria, SVP, Global Development, Oncology Kave Niksefat, SVP, Global Marketing & Access Dr. Charles Rudin, Director of Memorial Sloan Kettering Cancer Center
Page 4
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 4 • Our BiTE® platform demonstrates transformative survival benefit in hematologic malignancies and solid tumors • IMDELLTRA® demonstrates durable survival benefit in small cell lung cancer • IMDELLTRA® is becoming the cornerstone therapy for ES-SCLC, regardless of combination choice including PD-L1s • Broad global development program has the potential to further expand IMDELLTRA ®’s impact • Innovative Oncology portfolio is well positioned as one of Amgen’s six key growth drivers BiTE, bispecific T-cell engager; ES-SCLC, extensive-stage small cell lung cancer; PD -L1, programmed cell death ligand 1. Today’s Highlights
Page 5
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 5 Serving patient populations with significant unmet need Small Cell Lung Cancer Acute Lymphoblastic Leukemia Autoimmune Diseases Severe Asthma Osteoporosis Cardiovascular Disease Amgen Has a Strong Portfolio of First-in-Class and Best-in-Class Medicines
Page 6
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 6 ~70% of Q2 Sales generated by the six key growth drivers +37% +38% +42% Rare Disease +21% Q2 2026 Sales Growth (YoY) +18% Innovative Oncology * +29% Biosimilars *Innovative Oncology Includes Blincyto®, Imdelltra®, Kyprolis®, Lumakras®, Nplate®, Vectibix®. YoY = year over year. Amgen’s Six Key Growth Drivers Grew 26% YoY in Q2 2026 and Comprised ~ 70% of Q2 Product Sales
Page 7
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 7 IMMUNO-ONCOLOGY PRECISION THERAPIES Amgen’s Oncology Strategy is Anchored in Two Core Pillars Fc = fragment crystallizable region; CD3, cluster of differentiation 3; DLL3, delta -like ligand 3; mAb, monoclonal antibody. 1. Image adapted from Fu, Z., Li, S., Han, S. et al. Antibody drug conjugate: the “biological missile” for targeted cancer th erapy. Sig Transduct Target Ther 7, 93 (2022). https://doi.org/10.1038/s41392-022-00947-7 Focused on differentiated, transformative therapies for hard-to-treat solid tumors and hematologic malignancies Cell-intrinsic therapeutics Combines the specificity of mAb with potency of payloads T-cell mediated killing to eradicate tumors Bispecific T-Cell Engagers (BiTE®) Antibody-Drug Conjugates (ADC)Small Molecules Anti-CD3 Anti-DLL3 Fc Linker & Payload Antibody
Page 8
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 8 One transformative molecule: BLINCYTO ® Hematologic malignancies Continuous IV administration Inpatient hospital administration Frequent CRS events Amgen Has Pioneered Bispecific T-Cell Engager (BiTE®) Medicines IV, intravenous; CRS, cytokine release syndrome; Ph3, Phase 3. BiTE® Medicines TODAYWhere BiTE® Started Multiple transformative molecules: BLINCYTO ®, IMDELLTRA ®, Xaluritamig (in Ph3) Hematologic malignancies & solid tumors IV infusion with the potential for subcutaneous administration in the future Evolving administration requirements (reduced monitoring for IMDELLTRA ®) Management strategies for CRS
Page 9
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 9 BiTE, bispecific T-cell engager; STEAP1, six -transmembrane epithelial antigen of the prostate 1; 1. Xu M, et al. Cancers (Basel). 20 22;14:4034. 2. Nolan-Stevaux O, et al. Cancer Res. 2020;80(16 suppl):DDT02-03. 3. Nolan-Stevaux O. Slides presented at: American Association for Cancer Research Virtual Annual Meeting I; April 27 -28, 2020. Abstract DDT02-03. 4. Decato BE, Poster presented at American Association for Cancer Research Virtual Annual Meeting: April 25 -30, 2025. Xaluritamig Mechanism of Action No biomarker testing needed for Xaluritamig as STEAP1 is expressed in >95% mCRPC tumors4 STEAP1 is Broadly Expressed3 STEAP1 is a cell surface antigen, highly expressed in prostate cancer and associated with poor survival 1,2 Xaluritamig mCRPC Normal prostate Xaluritamig, in Phase 3 development, has the Potential to Extend the Impact of the BiTE® Platform into Prostate Cancer
Page 10
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 10 Xaluritamig is Being Investigated Across Multiple Disease Settings Abi, abiraterone; BCR, biochemical recurrence; ADT, androgen deprivation therapy; chemo, chemotherapy; Tx, treatment; nmHSPC, nonmetastatic hormone-sensitive prostate cancer; mHSPC, metastatic hormone -sensitive prostate cancer; mCRPC, metastatic castration -resistant prostate cancer. Nonmetastatic Disease (nmHSPC) •~200-300K •Eligible U.S. patients Phase 1b Neoadjuvant (Enrolling) Phase 1b BCR (Ongoing) Biochemical Recurrence Localized Disease Metastatic Disease (mHSPC) Chemo-Naïve (mCRPC) Post-taxane (mCRPC) •~30-40K •Eligible U.S. patients •~45-55K •Eligible U.S. patients Phase 3 XALience combo with abi vs SOC (Enrolling) •~10-20K •Eligible U.S. patients Phase 3 XALute monotherapy vs SOC (Fully enrolled) ADT Initiation Resistance to Hormonal Tx Resistance to Chemo Tx Phase 1b combo with ADT and abi or darolutamide (Enrolling) Prostate Cancer Disease Progression
Page 11
IMDELLTRA® (tarlatamab-dlle)
Page 12
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 12 Recent Advancements have Generated Modest Improvements in Overall Survival in First-line Small Cell Lung Cancer Note: Cross-trial comparisons are not appropriate due to differences in study design, patient populations, treatment protocols, and other trial-specific factors. *DeLLphi-305 trial is sponsored by Amgen, with partial funding and IMFINZI ® provided by AstraZeneca. Atezo, atezolizumab; Lurbi, lurbinectedin; chemo, chemotherapy; 1L, first -line; 1LM, first-line maintenance; ES-SCLC, extensive-stage small cell lung canc er. 1. Horn et al, NEJM 2018. 2. Paz-Ares L, et al, ESMO Open. 2022;7:100408. 3. Paz-Ares et al, Lancet 2025; 405:2129-43. 1L M post PD-L1 induction DeLLphi 305 1L DeLLphi 303 Atezolizumab + Chemo in 1L ES-SCLC1 months Median Overall Survival IMFINZI® (durvalumab) + Chemo in 1L ES-SCLC2 months Median Overall Survival Atezolizumab + Lurbinectedin in 1LM ES-SCLC3 months Median Overall Survival What will IMDELLTRA® + IMFINZI® demonstrate in 1L Maintenance in ES-SCLC? (Phase 3 DeLLphi-305*) 12.3 12.9 13.2 Phase 3 IMpower133 Phase 3 CASPIAN Phase 3 IMforte
Page 13
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 13 IMDELLTRA® Plus a PD-L1 Delivered 37.9 Months of Survival in SCLC in a Phase 1b First-Line Maintenance Study (DeLLphi-303) Overall survival with IMDELLTRA ® + anti-PD-L1 as 1L maintenance therapy from Phase 1b DeLLphi -303 88 86 81 73 63 53 49 36 32 29 26 18 13 4 1 0 Patients at risk: 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 Months from start of maintenance treatment OS (%) 100 80 60 40 20 0 58% 50% IMDELLTRA® + Anti-PD-L1 Overall IMDELLTRA® + Anti-PD-L1 mOS (95% CI), months 37.9 (22.5–NE) mFU*, months 30.882% • Median OS for patients with ES -SCLC treated in 1L maintenance with atezolizumab + lurbinectedin in the Ph3 IMForte study was 13.2 months. 1 • In the Phase 1b DeLLphi -303 study, IMDELLTRA ® combined with a PD -L1 inhibitor as 1L maintenance therapy demonstrated encouraging antitumor activity and positive benefit /risk profile 2,3 IMDELLTRA® + PD-L1 has the potential for durable survival *Survival follow -up remains ongoing. 1L, first -line; CI, confidence interval; ES -SCLC, extensive -stage small cell lung cancer; mFU, median follow up; mOS, median overall survival; NE, not estimable; OS, overall survival; Ph3, Phase 3; PD -L1, programmed cell death ligand. 1. Paz-Ares et al. Lancet 2025; 405:2129 -43. 5. Paulson K, et al. Lancet Oncol. 2025;26:1300–1311. 6. Wermke M et al. 3821P. Poster presented at ESMO Congress Oct 23 -27, 2026; Madrid, Spain.
Page 14
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 14 IMDELLTRA® plus IMFINZI® vs IMFINZI® as first-line maintenance therapy following first-line IMFINZI®, platinum, and etoposide in extensive-stage small cell lung cancer: primary analysis of the phase 3 DeLLphi-305 trial Jacob Sands, Tatsuya Yoshida, Myung -Ju Ahn, Carl M. Gay, Martin Schuler, Haifeng Liu, Ahmet Sezer, Ahmet Bilici, Ippokratis Korantzis, Sun Min Lim, Isamu Okamoto, Oscar Juan-Vidal, Yuanbin Chen, Gustavo Schvartsman, Anne-Marie C. Dingemans, Jeffrey M. Clarke, Miguel Marigil, Yuyang Zhang, Bazle Abidi, Maurice Pérol PRESENTER: Dr. Charles Rudin, MD PhD Director of Memorial Sloan Kettering Cancer Center New York, NY, United States of America
Page 15
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 15 DeLLphi-305 Study Design A Phase 3, Open -label, Multicenter, Randomized Study of IMDELLTRA ® in Combination With IMFINZI ® vs IMFINZI ® Alone in Patients With ES -SCLC Following Platinum, Etoposide and IMFINZI® (NCT06211036) Stratification Factors • Brain and/or liver metastasis (Yes/No) • Response to 1L chemo -IO (PR/CR vs SD) • Prior platinum type (cisplatin vs carboplatin) 1L Chemo-IO Platinum-etoposide + IMFINZIa induction therapy (4 cycles) Key Inclusion Criteria • Age ≥ 18 years • No disease progression • ECOG PS 0–1 • Asymptomatic untreated or treated brain metastasis R 1:1 N = 563 IMDELLTRA® (10 mg Q2W)b + IMFINZI® (1500 mg Q4W)c n = 282 IMFINZI® (1500 mg Q4W)c n = 281 Treatment until progression or unacceptable toxicity Primary Endpoint: OS Key Secondary Endpoint: PFS Secondary Endpoints: ORR, DOR, safety Interim analysis for OS: 243 (61% IF) OS events, 0.008 two-sided P-value boundary Endpoints were tested sequentially according to a prespecified hierarchical testing strategy: OS → PFS → ORR Data cut-off date: 7 JUL 2026. aEligible patients must have received ≥ 3 cycles of concomitant IMFINZI ® as 1L treatment of ES-SCLC. bPatients were monitored on site for a minimum of 1 to 2 hours, or 6 to 8 hours in certain regions after the first two doses of IMDELLTRA ®. cEach treatment cycle consists of 28 days. 1L, first line; CR, complete response; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; ES-SCLC, extensive-stage small cell lung cancer; IF, information fraction; IO, immunotherapy; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; Q2W, once every two weeks; Q4W, once every four weeks; R, randomization; SD, stable disease. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06211036. Accessed 31 August 2026.
Page 16
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 16 Baseline Characteristics Characteristics IMDELLTRA® + IMFINZI ® (n = 282) IMFINZI ® (n = 281) Age, median (range), years 65.0 (35–87) 65.0 (29–86) Male, % 69.9 71.5 Race, White/Non -white, % 57.8 / 42.2 64.4 / 35.6 Region, Americas/Asia -Pacific/Europe, % 12.8 / 40.4 / 46.8 13.9 / 35.9 / 50.2 ECOG PS, 0/1, % 45.7 / 54.3 43.1 / 56.9 Smoking history, Yes/Never, % 90.4 / 9.2 90.8 / 8.5 Limited -Stage SCLC at initial diagnosis, % 5.3 2.5 Type of platinum first received, cisplatin/ carboplatin a, % 15.6 / 84.4 15.7 / 84.0 Response to initial therapy, CR/PR/SD , % 3.2 / 85.8 / 11.0 3.6 / 84.7 / 11.7 Presence of current/prior brain metastasis, % 19.5 19.9 Presence of current/prior liver metastasis, % 31.2 33.8 aIn IMFINZI arm, one patient received carboplatin, but the dosage is not available. CR, complete response; ECOG PS, Eastern Coope rative Oncology Group performance status; SCLC, small cell lung cancer; PR, partial response; SD, stable disease. • At baseline, key characteristics were well balanced between the treatment arms • Prior or current brain and/or liver metastases were observed in a meaningful proportion of patients
Page 17
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 17 IMDELLTRA® + IMFINZI® (n = 282) IMFINZI® (n = 281) Median OS, months (95% CI) 21.1 (20.8–NE) 12.7 (11.2–14.8) Median FU, months 15.9 16.1 HR (95% CI); P-value (2-sided)a 0.42 (0.32–0.54); P < 0.001 281 252 208 171 146 81 33 8 1 0 282 276 258 246 222 132 55 9 0 0 20 40 60 80 100 0 3 6 9 12 15 18 21 24 27 92% 75% 79% 53% IMFINZI® IMDELLTRA® + IMFINZI® Percentage of Patients Number of patients at risk: Months Data cut-off date: 7 JUL 2026. At the time of data cut -off, 87 events had occurred in the IMDELLTRA ® + IMFINZI® arm, and 156 events had occurred in the IMFINZI ® arm. aP value was calculated using a stratified log -rank test. CI, confidence interval; FU, follow-up; HR, hazard ratio; NE, not estimable; OS, overall survival. IMDELLTRA® Plus IMFINZI® Significantly Improved Overall Survival Versus IMFINZI® Alone as First-line Maintenance Therapy IMDELLTRA® + IMFINZI® IMFINZI®
Page 18
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 18 0.40 (0.19–0.85) 0.42 (0.32–0.56) 0.49 (0.26–0.93) 0.41 (0.30–0.54) 0.82 (0.39–1.71) 0.43 (0.28–0.67) 0.36 (0.25–0.52) 0.47 (0.30–0.74) 0.40 (0.29–0.56) - - 0.56 (0.33–0.94) 0.38 (0.28–0.51) 0.48 (0.34–0.67) 0.36 (0.24–0.54) 21 / 33 135 / 248 130 / 225 26 / 56 89 / 141 51 / 101 16 / 39 3 / 4 45 / 92 0 / 4 108 / 181 36 / 80 120 / 201 87 / 148 69 / 133 10 / 31 77 / 251 0.41 (0.28–0.61) 0.40 (0.28–0.57)87 / 186 69 / 95 44 / 194 43 / 88 72 / 227 15 / 55 42 / 132 32 / 114 13 / 36 2 / 6 31 / 109 0 / 4 54 / 163 23 / 85 64 / 197 53 / 143 34 / 139 SD CR/PR Response to initial therapy No Yes Presence (previous or current) of liver metastases No Yes Presence (previous or current) of brain metastases Europe Asia-Pacific Americas Region Other Asian Black White Race Female Male Sex ≥ 65 years < 65 years Age 0.1 0.2 0.5 1 1.5 2 IMDELLTRA® + IMFINZI® Better Type of platinum first received for ES-SCLC Carboplatin Cisplatin 0.44 (0.34–0.59) 0.33 (0.16–0.67) 132 / 236 23 / 44 76 / 238 11 / 44 Hazard Ratio for Death (95% CI) Subgroup IMDELLTRA® + IMFINZI® IMFINZI® no. of events / no. of patients Data cut-off date: 7 JUL 2026. Median follow-up: 15.9 months (IMDELLTRA® + IMFINZI ® arm); 16.1 months (IMFINZI ® arm). CI, confidence interval; ES-SCLC, extensive-stage small cell lung cancer; CR, complete response; OS, overall survival; PR, partial response; SD, stable disease. OS Benefit Was Consistent Across All Key Prespecified Subgroups IMFINZI® Better
Page 19
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 19 IMDELLTRA® + IMFINZI® (n = 282) IMFINZI® (n = 281) Median PFS, months (95% CI) 7.4 (5.6–9.1) 1.9 (1.9–2.0) Median FU, months 13.9 13.9 HR (95% CI); P-value (2-sided)a 0.34 (0.28–0.42); P < 0.001 281 282IMDELLTRA® + IMFINZI® IMFINZI® 106 46 36 18 8 2 0 225 147 122 86 32 14 1 0 Number of patients at risk: Percentage of Patients 0 20 40 60 80 100 Months 0 3 6 9 12 15 18 21 24 53% 38% 17% 10% IMFINZI® Data cut-off date: 7 JUL 2026. At the time of data cut -off, 182 events had occurred in the IMDELLTRA®+IMFINZI® arm, and 250 events had occurred in the IMFINZI ® arm. aP-value was calculated using a stratified log -rank test. CI, confidence interval; FU, follow-up; HR, hazard ratio; PFS, progression -free survival. IMDELLTRA® Plus IMFINZI® Significantly Improved PFS Versus IMFINZI® Alone IMDELLTRA® + IMFINZI®
Page 20
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 20 Hazard Ratio for Disease Progression or Death (95% CI) SD CR/PR Response to initial therapy No Yes Presence (previous or current) of liver metastases No Yes Presence (previous or current) of brain metastases Europe Asia-Pacific Americas Region Other Asian Black White Race Female Male Sex ≥ 65 years < 65 years Age 0.30 (0.22–0.40) 0.35 (0.26–0.48) 0.54 (0.31–0.93) 0.38 (0.27–0.52) 0.34 (0.26–0.44) 0.33 (0.23–0.47) 0.36 (0.28–0.45) - - 0.38 (0.29–0.50) 0.32 (0.24–0.42) 90 / 101 31 / 39 129 / 141 4 / 4 4 / 4 81 / 92 161 / 181 74 / 80 176 / 201 131 / 148 119 / 133 82 / 132 0.50 (0.28–0.88) 0.33 (0.27–0.41) 0.34 (0.27–0.44) 0.34 (0.25–0.47) 0.36 (0.29–0.44) 0.33 (0.21–0.51) 29 / 33 221 / 248 159 / 186 91 / 95 199 / 225 51 / 56 21 / 31 161 / 251 111 / 194 71 / 88 146 / 227 36 / 55 77 / 114 23 / 36 3 / 6 75 / 109 1 / 4 103 / 163 54 / 85 128 / 197 96 / 143 86 / 139 Subgroup no. of events / no. of patients 0.2 0.4 0.6 1 1.4 2 Type of platinum first received for ES-SCLC Carboplatin Cisplatin 0.38 (0.30–0.47) 0.23 (0.14–0.39) 208 / 236 41 / 44 156 / 238 26 / 44 PFS Favored IMDELLTRA® Plus IMFINZI® Across Prespecified Subgroups Data cut-off date: 7 JUL 2026. Median follow-up: 13.9 months (IMDELLTRA® + IMFINZI® arm); 13.9 months (IMFINZI® arm). CI, confidence interval; CR, complete response; ES-SCLC, extensive-stage small cell lung cancer; PFS, progression-free survival; PR, partial response; SD, stable disease. IMDELLTRA® + IMFINZI® IMFINZI® IMDELLTRA® + IMFINZI® Better IMFINZI® Better
Page 21
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 21 IMDELLTRA® + IMFINZI ® (n = 235)a IMFINZI ® (n = 244)a BOR, n (%)a,b Confirmed CRc 2 (0.9) 1 (0.4) Confirmed PRc 60 (25.5) 9 (3.7) Stable disease 127 (54.0) 74 (30.3) Progressive disease 43 (18.3) 150 (61.5) ORR, % (95% CI) 26.4 (20.9–32.5) 4.1 (2.0–7.4) P-value (2-sided) < 0.001 Median DOR, months (95% CI) 12.7 (7.4–NE) 5.6 (3.6–NE) 70% 52% 38% 0 3 6 9 Months 12 15 10 10 3 0 62 58 36 27 11 5 18 0 Number of patients at risk: 0 20 40 60 80 100 IMDELLTRA® + IMFINZI® Responders Without Progression or Death Duration of response IMDELLTRA® Plus IMFINZI® Demonstrated Significantly Improved Objective Response Rate Versus IMFINZI® Alone Data cut-off date: 7 JUL 2026. Median follow-up: 10.2 months (IMDELLTRA® + IMFINZI® arm); 8.3 months (IMFINZI® arm). aBased on RECIST 1.1 per investigator assessment in patients with measurable disease at baseline at the time of randomization. bPostbaseline scan data was not available for 3 (1.3%) patients in IMDELLTRA® + IMFINZI® arm and 10 (4.1%) in IMFINZI® arm. cConfirmation of a CR or a PR was required and had to take place no fewer than 4 weeks after the initial documentation of a CR or a PR. 1L, first line; BOR, best overall response; CI, confidence interval; CR, complete response; DOR, duration of response; NE, not estimable; ORR, objective response rate; PR, partial response, RECIST, Response Evaluation Criteria in Solid Tumors. As of data cut-off, 43.6% and 11.4% of patients remained on treatment in IMDELLTRA® plus IMFINZI® and IMFINZI® arm, respectively IMDELLTRA® + IMFINZI® IMFINZI® IMFINZI®
Page 22
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 22 IMDELLTRA® + IMFINZI® (n = 282) IMFINZI® (n = 278) Median duration of treatment, weeks (IQR) 46.9 (16.4–65.6) 8.1 (4.1–20.1) Any grade TEAEs, n (%) 281 (99.6) 258 (92.8) Grade ≥ 3, n (%) 132 (46.8) 113 (40.6) Serious, n (%) 118 (41.8) 88 (31.7) Fatal, n (%) 13 (4.6) 13 (4.7) Leading to discontinuation of IMDELLTRA ®, n (%) 16 (5.7) NA Leading to discontinuation of IMFINZI ®, n (%) 16 (5.7) 16 (5.8) Any grade, TRAEsa, n (%) 268 (95.0) 145 (52.2) Grade ≥ 3, n (%) 59 (20.9) 30 (10.8) Serious, n (%) 63 (22.3) 26 (9.4) Fatal, n (%) 0 (0.0) 2 (0.7) Leading to discontinuation of IMDELLTRA ®, n (%) 9 (3.2) NA Leading to discontinuation of IMFINZI ®, n (%) 9 (3.2) 10 (3.6) IMDELLTRA® Plus IMFINZI® Showed a Manageable Safety Profile Consistent with the Individual Agents Data cut-off date: 7 JUL 2026. aRelated to any treatment. AST, aspartate aminotransferase; IQR, interquartile range; NA, not applicable; TEAE, treatment -emergent adverse events; TRAE, treatment -related adverse events. • The grade ≥ 3 TRAEs occurring in ≥ 1% of the patients included neutrophil count decreased, neutropenia, and decreased appetite in the IMDELLTRA® plus IMFINZI® arm, and pneumonitis, AST increased and lipase increased in the IMFINZI® arm • Treatment with IMDELLTRA® plus IMFINZI® resulted in a low frequency of treatment discontinuations and no treatment-related fatalities
Page 23
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 23 CRSa,b, n (%) IMDELLTRA® + IMFINZI® (n = 282) IMFINZI® (n = 278) Any grade 140 (49.6) 4 (1.4) Grade 2 21 (7.4) 2 (0.7) Grade 3 1 (0.4) 0 (0.0) Grade 4 0 (0.0) 0 (0.0) Serious adverse events 36 (12.8) 2 (0.7) Leading to discontinuation ofIMDELLTRA® 1 (0.4) NA Fatal adverse events 0 (0.0) 0 (0.0) Utilization of any CRS interventionsc 65 (23.0) 2 (0.7) ICANSd, n (%) IMDELLTRA® + IMFINZI® (n = 282) IMFINZI® (n = 278) Any grade 3 (1.1) 0 (0.0) Grade 2 1 (0.4) 0 (0.0) Grade 3 0 (0.0) 0 (0.0) Grade 4 0 (0.0) 0 (0.0) Serious adverse events 0 (0.0) 0 (0.0) Leading to discontinuation of IMDELLTRA® 0 (0.0) NA Fatal adverse events 0 (0.0) 0 (0.0) CRS and ICANS Events Profile is Consistent with The Known Safety Profile of IMDELLTRA® Data cut-off date: 7 JUL 2026. aCRS events included one patient with cytokine storm. bCRS and ICANS events were graded using ASTCT 2019 criteria. cOther supportive care interventions included intravenous fluids, vasopresser, and supplemental (low-flow [≤ 6 L/min]) oxygen. dPotentially associated neurologic events (including ICANS) occurred in 27 (9.6%) and 19 (6.8%) patients, respectively. Events were predom inantly grade 1 or 2 and no fatal events occurred. ASTCT, American Society for Transplantation and Cellular Therapy; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; NA, not applicable. Most CRS events resolved with supportive care (and antipyretics): Interventions included corticosteroids (21.6%), tocilizumab (3.9%), and low-flow oxygen (1.4%)
Page 24
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 24 Conclusions • IMDELLTRA® plus IMFINZI® significantly improved OS, PFS, and ORR versus IMFINZI® alone in patients with ES-SCLC without progression after initial chemo plus IMFINZI® o 58% reduction in the risk of death ; P < 0.001 o 66% reduction in the risk of disease progression or death ; P < 0.001 o ORR: 26.4% vs 4.1%; P < 0.001 • Survival benefit extended to all pre-defined subgroups including patients with brain metastases, liver metastases, or minimal response to initial chemo plus IMFINZI® • IMDELLTRA® plus IMFINZI® demonstrated a positive benefit/risk profile with low rates of treatment discontinuation due to adverse events Chemo, chemotherapy; CRS, cytokine release syndrome; DOR, duration of response; ES -SCLC, extensive-stage small cell lung cancer; ICANS, immune effector cell-associated neurotoxicity syndrome; ORR, objective response rate; OS, overall survival; PFS, progression-free survival. • DeLLphi-305 outcomes support IMDELLTRA® plus IMFINZI® as a new standard of care for first-line maintenance therapy in ES-SCLC
Page 25
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 25 Simultaneously Published in the New England Journal of Medicine
Page 26
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 26 Acknowledgements Copies of this presentation obtained through QR, AR and/or text key codes are for personal use only and may not be reproduced without written permission of the authors. We gratefully acknowledge Ying Cheng, M.D. (Jilin Cancer Hospital, Changchun, China), for her contributions as the China leading principal investigator and scientific leadership. We thank all the patients, their families, the DeLLphi -305 investigators, and clinical site support staff. DeLLphi-305 was funded by Amgen (Study Sponsor) and AstraZeneca. Author Affiliations: Jacob Sands, MD: Dana-Farber Cancer Institute Boston, MA, United States of America; Tatsuya Yoshida, MD, PhD: National Cancer Center Hospital, Tokyo, Japan; Myung-Ju Ahn, MD, PhD: Samsung Medical Center; Hanyang University Medical Center, Seoul, Republic of Korea; Carl M. Gay, MD, PhD: University of Texas MD Anderson Cancer Center, Houston, TX, United States of America; Martin Schuler, MD: West German Cancer Center, University Hospital Essen, Essen, Germany; Haifeng Liu, MD: Jilin Cancer Hospital, Changchun, China; Ahmet Sezer, MD: Medical Park Seyhan Hastanesi, Adana, Turkiye; Ahmet Bilici, MD: Istanbul Medipol University, Bagcilar Medipol Mega Universite Hastanesi, Istanbul, Turkiye; Ippokratis Korantzis, MD: Saint Luke’s Hospital, Thessaloniki, Greece; European Interbalkan Medical Center, Thessaloniki, Greece; Sun Min Lim, MD, PhD: Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Isamu Okamoto MD, PhD: Kyushu University Hospital, Japan; Oscar Juan-Vidal, MD, PhD: Hospital Universitari i Politècnic La Fe, Valencia, Spain; Yuanbin Chen, MD, PhD: Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, United States of America; Orlando Health Cancer Institute, Orlando, FL, United States of America; Gustavo Schvartsman, MD, PhD: Hospital Israelita Albert Einstein, São Paulo, Brazil; Anne-Marie C. Dingemans, MD, PhD: Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands; Jeffrey M. Clarke, MD: Duke Cancer Center, Durham, NC, United States of America; Miguel Marigil, MD, PhD: Amgen Inc., Thousand Oaks, CA, United States of America; Yuyang Zhang, PhD: Amgen Inc., Thousand Oaks, CA, United States of America; Bazle Abidi, MD: Amgen Inc., Thousand Oaks, CA, United States of America; Maurice Pérol, MD: Léon Bérard Cancer Center, Lyon, France
Page 27
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 27 SCLC, small cell lung cancer; 1LM, first -line maintenance; 1L, first -line; LS, limited-stage; Alt IV, alternative intravenous do sing; 2L, second-line, SC, subcutaneous; ADC, antibody drug conjugate; PD -L1, programmed cell death ligand 1; DLL3, Delta -like canonical Notch ligand 3; 1. Sands J, Yoshida T, Ahn M -J, et al. Abstract #755. Presented at: European Society for Medical Oncology Congress; October 23-27, 2026; Madrid, Spain. 2. Rudin CM, Ahn M -J, Schuler M, et al. Abstract #6617. Presented at: European Society for Medical O ncology Congress; October 23-27, 2026; Madrid, Spain. 3. Goldman J et al. OA05.01. Oral presentation at WCLC Congress Sep 12 -15, 2026; Seoul, Korea. 4. Mountzio G, et al. N Engl J Med 2025;393:349 -61. Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward -looking statements, actual re sults may vary materially; Amgen disclaims any duty to update. TRANSFORM FRONTLINE SURVIVAL Phase 1b Phase 2 Phase 3 1LM Phase 3 (DeLLphi-305) 21.1 months (est. mOS)1 1LM Phase 1b (DeLLphi-303) 37.9 months (mOS)2 1L Phase 3 (DeLLphi-312) Enrollment Completed LS Phase 3 (DeLLphi-306) Enrollment Completed Pursuing a Broad Clinical Development Program to Establish IMDELLTRA® as the Cornerstone Therapy in SCLC FLEXIBLE DOSING Alt IV Dosing in 2L (DeLLphi-309) Primary Analysis Completed3 SC Tarlatamab in 2L (DeLLphi-315) Enrolling BECOME THE CORNER - STONE 2L Phase 3 (DeLLphi-304) 13.6 months (mOS)4 Combo with B7-H3 ADC +/- PD-L1 (DeLLphi-310) Enrollment Completed Combo with DLL3 ADC +/- PD-L1 (DeLLphi-313) Enrolling IMPACT BEYOND SCLC Neuroendocrine carcinomas and other DLL3-expressing malignancies
Page 28
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 28 IMDELLTRA®: The Established Standard of Care in 2L+ ES-SCLC • Extending the median overall survival by more than five months to 13.6 months vs. standard of care chemotherapy at 8.3 months • Recommended by NCCN as the Category 1 preferred option after platinum -based chemotherapy 2L, second -line; ES -SCLC, extensive stage small cell lung cancer; NCCN, National Comprehensive Cancer Network. Revolutionized Survival in 2L+ ES-SCLC • Over 18K patients treated since launch globally • Adoption is expanding and is available at more than 2,000 U.S. sites of care, over 65% of sites that have used IMDELLTRA® are in the community setting Approved in 50+ Markets Globally • Chemotherapy remains a common treatment option • Recommended on -site monitoring has decreased from 22–24 hours to 6–8 hours (in the U.S. and EU) • 14k eligible U.S. patients with 2L+ ES-SCLC Significant Opportunity Remains in the 2L+ Setting
Page 29
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 29 Moving IMDELLTRA® Earlier in the SCLC Treatment Continuum SOC, standard of care; PD -L1, programmed cell death ligand 1; chemoRT, chemoradiotherapy. 1. Rudin CM, et al. Nat Rev Dis Primers. 2021;7:3. 2. Zhang Y, et al. Lancet Oncol. 2023;24:1206 -1218. Extensive Stage SCLC ~23K Eligible U.S. patients LS Phase 3 Monotherapy vs placebo following ChemoRT (DeLLphi-306) •~5K Eligible U.S. patients ~14K Eligible U.S. patients •Approved in the U.S. & EU + An Established SOC in 2L+ Become SOC in First-Line (1L) Limited Stage (LS) 2L+ Phase 3 monotherapy (DeLLphi-304) 1LM Phase 3 combination with PD-L1 vs. PD-L1 (DeLLphi-305) 1L Phase 3 combination with chemo and PD-L1 (DeLLphi-312) 1L/1LM Phase 1b combination with chemo and PD-L1 (DeLLphi-303) Small cell lung cancer accounts for an estimated 10–15% of newly diagnosed lung cancer cases worldwide1,2
Page 30
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 30 IMDELLTRA® has Demonstrated Transformative Overall Survival in First-line Small Cell Lung Cancer months Median Overall Survival months Median Overall Survival months Median Overall Survival 12.3 12.9 13.2 Phase 3 IMpower133 Phase 3 CASPIAN Phase 3 IMforte 1LM Phase 3 IMDELLTRA ® + IMFINZI® (DeLLphi-305)4,5 21.1 Est. Median Overall Survival (median follow-up of 15.9 months) 1LM Phase 1b IMDELLTRA ® + PD-L1 (DeLLphi-303)6 37.9 Median Overall Survival (median follow-up of 30.8 months) IMDELLTRA® Clinical Trials Note: Cross-trial comparisons are not appropriate due to differences in study design, patient populations, treatment protocols, and other trial-specific factors. Chemo, chemotherapy; 1L, first -line; 1LM, first-line maintenance; ES-SCLC, extensive-stage small cell lung cancer. 1. Horn et al, NEJM 2018. 2. Paz-Ares L, et al. ESMO Open. 2022;7:100408. 3. Paz-Ares et al, Lancet 2025; 405:2129-43. 4. Sands J, Yoshida T, Ahn M -J, et al. Abstract #755. Presented at: European Society for Medical Oncology Congress; October 23 -27, 2026; Madrid, Spain. 5. DeLLphi -305 trial is sponsored by Amgen, with partial funding and IMFINZI® provided by AstraZeneca. 6. Rudin CM, Ahn M-J, Schuler M, et al. Abstract #6617. Presented at: European Society for Medical Oncology Congress; October 23 -27, 2026; Madrid, Spain. months months Atezolizumab + Chemo in 1L ES-SCLC1 Atezolizumab + Lurbinectedin in 1LM ES-SCLC3 IMFINZI® (durvalumab) + Chemo in 1L ES-SCLC2
Page 31
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 31 FUTURE DOSING IMPROVEMENTS BIOSIMILARSUNPRECEDENTED DURABLE SURVIVAL CORNERSTONE THERAPY Broad Clinical Program Reach the broadest population by introducing IMDELLTRA ® at the earliest possible opportunities in SCLC and beyond 1LM Phase 3 (DeLLphi-305)1 21.1 months Est. Median Overall Survival (median follow-up of 15.9 months) 1LM Phase 1b (DeLLphi-303)2 37.9 months Median Overall Survival (median follow-up of 30.8 months) On-site monitoring for 6 to 8 hours for the first two doses of IMDELLTRA® as approved in the U.S. and EU With the potential for 1 to 2 hours monitoring for the first two doses* Less Frequent Dosing alternative IV dosing Q3W / Q4W** 1L, first-line; 1LM, first-line maintenance; Q3W, every 3 weeks; Q4W, every 4 weeks; SCLC, small cell lung cancer. * 1-2 hour monitoring is evaluated in Phase 3 DeLLphi -305, -306, -312, and -315; ** Less frequent dosing was evaluated in Phase 2 DeLLphi-309. 1. Sands J, Yoshida T, Ahn M -J, et al. Abstract #755. Presented at: European Society for Medical Oncology Congress; October 23 -27, 2026; Madrid, Spain. 2. Rudin CM, Ahn M-J, Schuler M, et al. Abstract #6617. Presented at: European Society for Medical Oncology Congress; October 23 -27, 2026; Madrid, Spain. IMDELLTRA® is Revolutionizing the Treatment of Small Cell Lung Cancer Across Multiple Dimensions of Care
Page 32
Provided Oct. 24, 2026, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update. 32 Q&A